Literature DB >> 11149048

The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.

O Nazli1, A D Bozdag, T Tansug, R Kir, E Kaymak.   

Abstract

BACKGROUND/AIMS: CA 19-9 and CEA were evaluated for their specificity and sensitivity in the early diagnosis of pancreatic carcinoma.
METHODOLOGY: This prospective study included 40 patients with pancreatic carcinoma. A control group of 60 patients were divided into two subgroups as upper gastrointestinal system malignancies and benign pancreatic disorders. CEA and CA 19-9 levels were measured in all the patients.
RESULTS: When the reference value of CA 19-9 was accepted as 74 U/mL, the specificity was 100% when pancreatic carcinoma was compared with benign disorders of the pancreas, but it's specificity for upper gastrointestinal malignancies was 60-90%. When the reference value of CEA was increased, the sensitivity had been decreased but the specificity had been increased when compared with the control group. If the reference value of CEA was accepted as 5 ng/mL, the specificity was 100% when pancreatic carcinoma was compared with acute or chronic pancreatitis, but it is less specific for the differential diagnosis of pancreatic carcinoma from the upper gastrointestinal malignancies.
CONCLUSIONS: With the progression of the pancreatic carcinoma, serum CEA level and the specificity of CEA were elevated similar to that of CA 19-9. However, the elevation of CEA specificity when compared with the control group was lower than the specificity of the CA 19-9 and the sensitivity of CA 19-9 was superior to that of CEA for pancreatic carcinoma. The level of CA 19-9 was increased with the development of early pancreatic cancer and this elevation steadily continued with the progression of the cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11149048

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  25 in total

1.  A multiplexed bead assay for profiling glycosylation patterns on serum protein biomarkers of pancreatic cancer.

Authors:  Chen Li; Eugene Zolotarevsky; Ian Thompson; Michelle A Anderson; Diane M Simeone; John M Casper; Michael C Mullenix; David M Lubman
Journal:  Electrophoresis       Date:  2011-07-06       Impact factor: 3.535

Review 2.  Exosomes in bodily fluids are a highly stable resource of disease biomarkers.

Authors:  Stephanie Boukouris; Suresh Mathivanan
Journal:  Proteomics Clin Appl       Date:  2015-03-19       Impact factor: 3.494

3.  Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers.

Authors:  Shalini Makawita; Chris Smith; Ihor Batruch; Yingye Zheng; Felix Rückert; Robert Grützmann; Christian Pilarsky; Steven Gallinger; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2011-06-07       Impact factor: 5.911

4.  Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers.

Authors:  Joshua D Cohen; Ammar A Javed; Christopher Thoburn; Fay Wong; Jeanne Tie; Peter Gibbs; C Max Schmidt; Michele T Yip-Schneider; Peter J Allen; Mark Schattner; Randall E Brand; Aatur D Singhi; Gloria M Petersen; Seung-Mo Hong; Song Cheol Kim; Massimo Falconi; Claudio Doglioni; Matthew J Weiss; Nita Ahuja; Jin He; Martin A Makary; Anirban Maitra; Samir M Hanash; Marco Dal Molin; Yuxuan Wang; Lu Li; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Natalie Silliman; Maria Popoli; Michael G Goggins; Ralph H Hruban; Christopher L Wolfgang; Alison P Klein; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Anne Marie Lennon
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

5.  Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy.

Authors:  Yi-Jun Kim; Hyeon Kang Koh; Eui Kyu Chie; Do-Youn Oh; Yung-Jue Bang; Eun Mi Nam; Kyubo Kim
Journal:  Int J Clin Oncol       Date:  2017-05-05       Impact factor: 3.402

6.  Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis.

Authors:  Zhe Huang; Fang Liu
Journal:  Tumour Biol       Date:  2014-05-01

7.  Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation.

Authors:  Cheng Xu; Yunfei Wang; Qiu Tu; Zhiye Zhang; Mengrou Chen; James Mwangi; Yaxiong Li; Yang Jin; Xudong Zhao; Ren Lai
Journal:  Oncogene       Date:  2018-10-24       Impact factor: 9.867

8.  Endoscopic ultrasonography in patients with elevated carbohydrate antigen 19-9 of obscure origin.

Authors:  Jae Hoon Cheong; Gwang Ha Kim; Ji Yoon Moon; Bong Eun Lee; Dong Yup Ryu; Dong Uk Kim; Hyung-Il Seo; Geun Am Song
Journal:  World J Gastrointest Endosc       Date:  2013-05-16

9.  CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent.

Authors:  Jonathan M Hernandez; Sarah M Cowgill; Sam Al-Saadi; Amy Collins; Sharona B Ross; Jennifer Cooper; Desireé Villadolid; Emmanuel Zervos; Alexander Rosemurgy
Journal:  J Gastrointest Surg       Date:  2008-10-30       Impact factor: 3.452

10.  [Pancreatic incidentalomas. Correct assessment and therapy].

Authors:  U Hopt; T Keck
Journal:  Chirurg       Date:  2007-08       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.